C.R. Bard

Rank: 24
2016 Rank30
R&D Spend:$292,800,000
Fiscal year ending:12-31-16
Click here to see all 100

C. R. Bard, Inc. is a multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the product fields of: Vascular, Urology, Oncology and Surgical Specialty. BARD markets its products and services worldwide to hospitals, individual health care professionals, extended care facilities and alternate site facilities.BARD pioneered the development of single-patient-use medical products for hospital procedures; today BARD is dedicated to pursuing technological innovations that offer superior clinical benefits while helping to reduce overall costs.

Bard Agrees to Acquire Liberator Medical. Bard Agrees to Acquire Full Ownership of its Joint Venture in Japan. Boston Scientific And C. R. Bard Announce Distribution Agreement For Lutonix Drug Coated Balloon.

Big 100 Mini Logo Key Personnel: Timothy Ring, chairman & CEO; John Weiland, vice chairman, president & COO; Christopher Holland, SVP & CFO; Jim Beasley, president; Timothy Collins, president; Sharon Luboff, VP; John Groetelaars, president; John DeFord, SVP, science, technology & clinical affairs; Samrat Khichi, SVP, general counsel & secretary; Patricia Christian, VP, regulatory affairs; Todd Garner, VP, IR; Tony Johnson, VP, global operations; Betty Larson, VP, HR; Scott Lowry, VP & Treasurer; Frank Lupisella Jr., VP & Controller; Gerard Porreca III, VP, quality, regulatory & medical affairs; Patrick Roche, VP, IT solutions; Richard Rosenzweig, VP, law & assistant secretary;

New Providence, New Jersey